Abstract:Two different mechanisms are considered to be the primary cause of aging. Cumulative DNA damage caused by reactive oxygen species (ROS), the by-products of oxidative phosphorylation, is one of these mechanisms (ROS concept). Constitutive stimulation of mitogen- and nutrient-sensing mTOR/S6 signaling is the second mechanism (TOR concept). The flow- and laser scanning- cytometric methods were developed to measure the level of the constitutive DNA damage/ROS- as well as of mTOR/S6- signaling in individual cells. Specifically, persistent activation of ATM and expression of γH2AX in untreated cells appears to report constitutive DNA damage induced by endogenous ROS. The level of phosphorylation of Ser235/236-ribosomal protein (RP), of Ser2448-mTOR and of Ser65-4EBP1, informs on constitutive signaling along the mTOR/S6 pathway. Potential gero-suppressive agents rapamycin, metformin, 2-deoxyglucose, berberine, resveratrol, vitamin D3 and aspirin, all decreased the level of constitutive DNA damage signaling as seen by the reduced expression of γH2AX in proliferating A549, TK6, WI-38 cells and in mitogenically stimulated human lymphocytes. They all also decreased the level of intracellular ROS and mitochondrial trans-membrane potential ΔΨm, the marker of mitochondrial energizing as well as reduced phosphorylation of mTOR, RP-S6 and 4EBP1. The most effective was rapamycin. Although the primary target of each on these agents may be different the data are consistent with the downstream mechanism in which the decline in mTOR/S6K signaling and translation rate is coupled with a decrease in oxidative phosphorylation, (revealed by ΔΨm) that leads to reduction of ROS and oxidative DNA damage. The decreased rate of translation induced by these agents may slow down cells hypertrophy and alleviate other features of cell aging/senescence. Reduction of oxidative DNA damage may lower predisposition to neoplastic transformation which otherwise may result from errors in repair of DNA sites coding for oncogenes or tumor suppressor genes. The data suggest that combined assessment of constitutive γH2AX expression, mitochondrial activity (ROS, ΔΨm) and mTOR signaling provides an adequate gamut of cell responses to evaluate effectiveness of gero-suppressive agents.

The mTORC1-autophagy pathway is a target for senescent cell elimination

Persistent mTORC1 signaling in cell senescence results from defects in amino acid and growth factor sensing

mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership

The mTOR–lysosome axis at the centre of ageing

mTORC2: A neglected player in aging regulation

With TOR, Less is More: A Key Role for the Conserved Nutrient-Sensing TOR Pathway in Aging

mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype

Targeting mTOR for Anti-Aging and Anti-Cancer Therapy

mTORC2 facilitates endothelial cell senescence by suppressing Nrf2 expression via the Akt/GSK-3β/C/EBPα signaling pathway

Targeting the biology of aging with mTOR inhibitors

The mTOR signaling pathway in cardiac aging

MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation

The Multifaceted Role of Nutrient Sensing and mTORC1 Signaling in Physiology and Aging

Mtor and S6k Play an Important Role in Ageing

Coupling shRNA screens with single-cell RNA-seq identifies a dual role for mTOR in reprogramming-induced senescence

Rapalink-1 reveals novel mTOR-dependent genes and an agmatinergic axis-based metabolic feedback regulating mTOR activity and lifespan

Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy

Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling

mTORC1 beyond anabolic metabolism: Regulation of cell death

Senescent Cell Depletion Through Targeting BCL-Family Proteins and Mitochondria

Senescence in the ageing skin: a new focus on mTORC1 and the lysosome